Psychopharmacology of chronic pain

Primary Psychiatry

Volumn 14, Issue 9, 2007, Pages 70-79

  Clark, Michael R ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CITALOPRAM; DESIPRAMINE; DOPAMINE RECEPTOR; DULOXETINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; ION CHANNEL; MIRTAZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORADRENALIN; NORTRIPTYLINE; OPIATE; PHENYTOIN; PREGABALIN; PSYCHOTROPIC AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

BONE MARROW SUPPRESSION; CHRONIC PAIN; COGNITIVE DEFECT; DIABETIC NEUROPATHY; DIZZINESS; FACILITATION; FIBROMYALGIA; HUMAN; LIVER TOXICITY; NAUSEA; NERVE CELL EXCITABILITY; NEUROPATHIC PAIN; NEUROTRANSMITTER RELEASE; NOCICEPTION; PERIPHERAL NEUROPATHY; POSTHERPETIC NEURALGIA; PSYCHOPHARMACOLOGY; REVIEW; TREMOR;

EID: 34848869639     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (191)

1. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12(1):13-21.
2. Nitu AN, Wallihan R, Skljarevski V, Ramadan NM. Emerging trends in the pharmacotherapy of chronic pain. Expert Opin Investig Drugs. 2003;12(4):549-559.
3. Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. CMAJ. 2006;175(3):265-275.
4. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006;81(4 suppl):S12-S25.
5. Attal N, Cruccu G, Haanpaa M, et al. EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13(11):1153-1169.
6. Gilron I, Bailey J, Weaver DF, Houlden RL. Patients' attitudes and prior treatments in neuropathic pain: a pilot study. Pain Res Manag. 2002;7(4):199-203.
7. Clark MR, Treisman GJ. Neurobiology of pain. Adv Psychosom Med. 2004;25:78-88.
8. Bolay H, Moskowitz M. Mechanisms of pain modulation in chronic syndromes. Neurology. 2002;59(5 suppl 2):S2-7.
9. Hunt SP, Mantyh PW. The molecular dynamics of pain control. Nat Rev Neurosci. 2001;2(2):83-91.
10. Zimmerman M. Pathobiology of neuropathic pain. Eur J Pharmacol. 2001;429(1-3):23-37.
11. Gidal BE. New and emerging treatment options for neuropathic pain. Am J Manag Care. 2006;12(9 suppl):S269-78.
12. Mattia C, Paoletti F, Coluzzi F, Boanelli A. New antidepressants in the treatment of neuropathic pain. A review. Minerva Anestesiol. 2002;68(3):105-114.
13. Coluzzi F, Mattia C. Mechanism-based treatment in chronic neuropathic pain: the role of antidepressants. Curr Pharm Des. 2005;11(23):2945-2960.
14. Dick IE, Brochu RM, Purohit Y, Kaczorowski GJ, Martin WJ, Priest BT. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J Pain. 2007;8(4):315-324.
15. Barkin RL, Fawcett J. The management challenges of chronic pain: the role of antidepressants. Am J Ther. 2000;7(1):31-47.
16. Paoli F, Darcourt G, Cossa P. Preliminary note on the action of imipramine in painful states [French]. Rev Neurol (Paris). 1960;102:503-504.
17. Clark MR. Pharmacological treatments for chronic non-malignant pain. Int Rev Psychiatry. 2000;12:148-156.
18. Saarto T, Wiffer PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2005;(3): CD005454.
19. Littlejohn GO, Guymer EK. Fibromyalgia syndrome: which antidepressant drug should we chose. Curr Pharm Dev. 2006;12(1):3-9.
20. Gerson MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132(1):397-414.
21. Walker EA, Roy-Byrne PP, Katon WJ, Jemelka R. An open trial of nortriptyline in women with chronic pelvic pain. Int J Psychiatry Med. 1991;21(3):245-252.
22. Phatak S, Foster HE. The management of interstitial cystitis: an update. Nat Clin Pract Urol. 2006;3(1):45-53.
23. Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis. 2003;36(7):877-882.
24. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118(3):289-305.
25. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage. 2000;20(6):449-458.
26. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83(3):389-400.
27. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology. 2000;55(7):915-920.
28. Richeimer SH, Bajwa ZH, Kahraman SS, Ransil BJ, Warfield CA. Utilization patterns of tricyclic antidepressants in a multidisciplinary pain clinic: a survey. Clin J Pain. 1997;13(4):324-329.
29. Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. J Pain. 2006;7(2):119-128.
30. Max MB. Treatment of post-herpetic neuralgia: antidepressants. Annal Neurol. 1994;35(suppl): S50-S53.
31. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain. 1992;49(2):205-219.
32. Berger A, Dukes EM, Edelsberg J, Stacey BR, Oster G. Use of tricyclic antidepressants in older patients with painful neuropathies. Eur J Clin Pharmacol. 2006;62(9):757-764.
33. Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves post-herpetic neuralgia. Clin Pharm Ther. 1990;47(3):305-312.
34. Sindrup SH, Ejlertsen B, Froland A, Sindrup EH, Brosen K, Gram LF. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Phar. 1989;37(2):151-153.
35. Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent, and neuropathic pain. Neuropharmacology. 2005;48(2):252-263.
36. Tokunaga A, Saika M, Senba E. 5-HT2A receptor subtype is involved in the thermal hyperalgesic mechanism of serotonin in the periphery. Pain. 1998;76(3):349-355.
37. Rani PU, Naidu MU, Prasad VB, Rao TR, Shobha JC. An evaluation of antidepressants in rheumatic pain conditions. Anesth Analg. 1996;83(2):371-375.
38. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112(3):191-197.
39. Tack J, Broekaert D, Fischler B, Oudenhove LV, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006;55(8):1095-1103.
40. Mojo PL, Cusi C, Sterzi RR, Canepari C. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev. 2005;(3):CD002919.
41. Ciaramella A, Grosso S, Poli P. Fluoxetine versus fluvoxamine for treatment of chronic pain. Minerva Anestesiol. 2000;66(1-2):55-61.
42. Max M, Lynch S, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. NEJM. 1992;326(19):1250-1256.
43. Sindrup SH, Gram LF, Brosen K, Eshoj O, Magensen EF. The SSRI paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990;42(2):135-144.
44. Sindrup SH, Bjerre U, Dejaard A, Brosen K, Aaes-Jorgensen T, Gram LF. The SSRI citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992;52(5):547-552.
45. Rowbotham MC, Reisner LA, Davies PS, Fields HL. Treatment response in antidepressant-naïve postherpetic neuralgia patients: double-blind, randomized trial. J Pain. 2005;6(11):741-746.
46. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry. 2001;13(1):31-41.
47. Giannopoulos S, Kosmidou M, Sarmas I, et al. Patient compliance with SSRIs and gabapentin in painful diabetic neuropathy. Clin J Pain. 2007;23(3):267-269.
48. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25(6):871-880.
49. Jones CK, Eastwood BJ, Need AB, Shannon HE. Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition. Neuropharmacology. 2006;51(7-8):1172-1180.
50. Beyreuther B, Callizot N, Stohr T. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol. 2006;539(1-2):64-70.
51. Lang E, Hord AH, Denson D. Venlafaxine hydrochloride (Effexor) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. Pain. 1996;68(1):151-155.
52. Yucel A, Ozyalcin S, Koknel Talu G, et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. Eur J Pain. 2005;9(4):407-416.
53. Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain. 2002;6(1):17-24.
54. Forssell H, Tasmuth T, Tenovuo O, Hampf G, Kalso E. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J Orofac Pain. 2004;18(2):131-137.
55. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110(3):697-706.
56. Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005;45(2):144-152.
57. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1-3):5-15.
58. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6(5):346-356.
59. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8):1411-1420.
60. Jones CK, Peters SC, Shannon HE. Synergistic interactions between the dual serotonergic, noradrenergic reuptake inhibitor duloxetine and the non-steroidal anti-inflammatory drug ibuprofen in inflammatory pain in rodents. Eur J Pain. 2007;11(2):208-215.
61. Ziegler D, Pritchett YL, Wang F, et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care. 2007;30(3):664-669.
62. Hardy T, Sachson R, Shen S, Armbruster M, Boulton AJ. Does treatment with duloxetine for neuropathic pain impact glycemic control. Diabetes Care. 2007;30(1):21-26.
63. Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med. 2006;7(5):373-385.
64. Perahia DG, Pritchett YL, Desaiah D, Raskin J. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol. 2006;21(6):311-317.
65. Freynhagen R, Vogt J, Lipfert P, Muth-Selbach U. Mirtazapine and its enantiomers differentially modulate acute thermal nociception in rats. Brain Res Bull. 2006;69(2):168-173.
66. Schreiber S, Rigai T, Katz Y, Pick CG. The antinociceptive effect of mirtazapine in mice is mediated through serotonergic, noradrenergic and opioid mechanisms. Brain Res Bull. 2002;58(6):601-605.
67. Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology. 2004;62(10):1706-1711.
68. Pedersen LH, Nielsen AN, Blackburn-Munro G. Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. Psychopharmacology. 2005;182(4):551-561.
69. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of buproprion SR for the treatment of neuropathic pain. Neurology. 2001;57(9):1583-1588.
70. Merikangas KR, Merikangas JR. Combination monoamine oxidase inhibitor and beta-blocker treatment of migraine, with anxiety and depression. Biol Psychiatry. 1995;38(9):603-610.
71. Pick CG, Paul D, Eison MS, Pasternak GW. Potentiation of opioid analgesia by the antidepressant nefazodone. Eur J Pharm. 1992;211(3):375-381.
72. Goodkin K, Gullion C, Agras WS. A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome. J Clin Psychopharmacol. 1990;10(4):269-278.
73. Marek GJ, McDougle CJ, Price LH, Seiden LS. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology. 1992;109(1-2):2-11.
74. Blackburn-Munro G, Erichsen HK. Antiepileptics and the treatment of neuropathic pain: evidence from animal models. Curr Pharm Des. 2005;11(23):2961-2976.
75. Soderpalm B. Anticonvulsants: aspects of their mechanisms of action. Eur J Pain. 2002;6 suppl A:3-9.
76. Waxman SG, Cummins TR, Black JA, Dib-Hajj S. Diverse functions and dynamic expression of neuronal sodium channels. Novartis Found Symp. 2002;241:34-51.
77. Blackburn-Munro G, Fleetwood-Walker SM. The sodium channel auxiliary subunits beta1 and beta2 are differentially expressed in the spinal cord of neuropathic rats. Neuroscience. 1999;90(1):153-164.
78. Baker MD, Wood JN. Involvement of Na+ channels in pain pathways. Trends Pharmacol Sci. 2001;22(1):27-31.
79. Waxman SG, Cummins TR, Dibhajj SD, Fjell J, Black JA. Sodium channels, excitability of primary sensory neurons and the molecular basis of pain. Muscle Nerve. 1999;22(9):1177-1187.
80. Bergouignan M. Successful cures of essential facial neuralgias by sodium diphenylhydantoinate [French]. Rev Laryngol Otol Rhinol. 1942;63:34-41.
81. Tanelian DL, Victory RA. Sodium channel-blocking agents: their use in neuropathic pain conditions. Pain Forum. 1995;4:75-80.
82. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conerence (EILAT VIII). Epilepsy Res. 2007;73(1):1-52.
83. Ettinger AB, Argoff CE. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics. 2007;4(1):75-83.
84. Stefan H, Feuerstein TJ. Novel anticonvulsant drugs. Pharmacol Ther. 2007;113(1):165-183.
85. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs. 2000;60(5):1029-1052.
86. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2000;(3):CD001133.
87. Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain. 2002;18(1):22-27.
88. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994;44(4):647-651.
89. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurology. 1995;52(3):281-286.
90. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol. 1997;54(9):1141-1145.
91. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17(2):103-108.
92. Rothrock JF. Clinical studies of valproate for migraine prophylaxis. Cephalalgia. 1997;17(2):81-83.
93. Cutrer FM. Antiepileptic drugs: how they work in headache. Headache. 2001;41(suppl 1):S3-10.
94. Cutrer FM, Moskowitz MA. Wolff Avard 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache. 1996;36(10):579-585.
95. Cutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia. 1997;17(2):93-100.
96. Houtchens MK, Richert JR, Sami A, Rose JW. Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler. 1997;3(4):250-253.
97. La Spina I, Porazzi D, Maggiolo F, Bottura P, Suter F. Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. Eur J Neurol. 2001;8(1):71-75.
98. To TP, Lim TC, Hill ST, et al. Gabapentin for neuropathic pain following spinal cord injury. Spinal Cord. 2002;40(6):282-285.
99. Wetzel CH, Connelly JF. Use of gabapentin in pain management. Ann Pharmacother. 1997;31(9):1082-1083.
100. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280(21):1831-1836.
101. Bone M, Critchley P, Buggy DJ. Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med. 2002;27(5):481-486.
102. Chandra K, Shafiq N, Pandhi P, Gupta S, Malhotra S. Gabapentin versus nortriptyline in postherpetic neuralgia patients: a randomized, double-blind clinical trial - the GONIP Trial. Int J Clin Pharmacol Ther. 2006;44(8):358-363.
103. Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain. 2001;17(4):284-295.
104. Rice AS, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94(2):215-224.
105. Rovibotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280(21):1837-1842.
106. Serpell MG, Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99(3):557-566.
107. Gustorff B, Nahlik G, Spacek A, Kress HG. Gabapentin in the treatment of chronic intractable pain [German]. Schmerz. 2002;16(1):9-14.
108. Alden KJ, Garcia J. Differential effect of gabapentin on neuronal and muscle calcium currents. J Pharmacol Exp Ther. 2001;297(2):727-735.
109. Luo ZD, Calcutt NA, Higuera ES, et al. Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther. 2002;303(3):1199-1205.
110. Feng Y, Cui M, Willis WD. Gabapentin markedly reduces acetic acid-induced visceral nociception. Anesthesiology. 2003;98(3):729-733.
111. Field MJ, McCleary S, Hughes J, Singh L. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain. 1999;80(1-2):391-398.
112. Xiao WH, Bennett GJ. Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats. J Pharmacol Exp Ther. 1995;274(2):666-672.
113. Dirks J, Peterson KL, Rowbotham MC, Dahl JB. Gabapentin suppresses cutaneous hyperalgesia following heat-capsaicin sensitization. Anesthesiology. 2002;97(1):102-107.
114. Bryans JS, Wustrow DJ. 3-substituted GABA analogs with central nervous system activity: a review. Med Res Rev. 1999;19(2):149-177.
115. Chen SR, Xu Z, Pan HL. Stereospecific effect of pregabalin on ectopic afferent discharges neuropathic pain induced by sciatic nerve ligation in rats. Anesthesiology. 2001;95(6):1473-1479.
116. Field MJ, Cox PJ, Stott E, et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A. 2006;103(46):17537-17542.
117. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73(2):137-150.
118. Han DW, Kweon TD, Lee JS, Lee YW. Antiallodynic effect of pregabalin in rat models of sympathetically maintained and sympathetic independent neuropathic pain. Yonsei Med J. 2007;48(1):41-47.
119. Sonnett TE, Setter SM, Campbell RK. Pregabalin for the treatment of painful neuropathy. Expert Rev Neurother. 2006;6(11):1629-1635.
120. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin. A novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007;29(1):26-48.
121. Van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin. 2006;22(2):375-384.
122. Crofford LJ, Rowbotham MC, Mease PJ, et al, Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(4):1264-1273.
123. Tarride JE, Gordon A, Vera-Llonch M, Dukes E, Rousseau C. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther. 2006;28(11):1922-1934.
124. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology. 2006;67(10):1792-1800.
125. Frese A, Husstedt IW, Ringelstein EB, Evers S. Pharmacologic treatment of central post-stroke pain. Clin J Pain. 2006;22(3):252-260.
126. Jose VM, Bhansali A, Hota D, Pandhi P. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet Med. 2007;24(4):377-383.
127. McCleane G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomized, double-blind, placebo controlled trial. Pain. 1999;83(1):105-107.
128. Devulder J. The relevance of monitoring lamotrigine serum concentrations in chronic pain patients. Acta Neurol Belg. 2006;106(1):15-18.
129. Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain. 2007;128(1-2):169-179.
130. Webb J, Kamali F. Analgesic effects of lamotrigine and phenytoin on cold-induced pain: a crossover placebo-controlled study in healthy volunteers. Pain. 1998;76(3):357-363.
131. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized controlled study. Neurology. 2001;57(3):505-509.
132. Coderre TJ, Kumar N, Lefebvre CD, Yu JS. A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. J Neurochem. 2007;100(5):1289-1299.
133. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia. 1997;38(8):859-880.
134. Benoliel R, Tal M, Eliav E. Effects of topiramate on the chronic constriction injury model in the rat. J Pain. 2006;7(12):878-883.
135. Donofrio PD, Raskin P, Rosenthal NR, et al. Safety and effectivenss of topiramate for the management of painful diabetic peripheral neuropathy in an open-label extension study. Clin Ther. 2005;27(9):1420-1431.
136. Khoromi S, Patsalides A, Parada S, Salehi V, Meegan JM, Max MB. Topiramate in chronic lumbar radicular pain. J Pain. 2005;6(12):829-836.
137. Vinik A. Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab. 2005;90(8):4936-4945.
138. Silberstein SD, Hulihan J, Karim MR, et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther. 2006;28(7):1002-1011.
139. Van Passel L, Arif H, Hirsch LJ. Topiramate for the treatment of epilepsy and other nervous system disorders. Expert Rev Neurother. 2006;6(1):19-31.
140. Meuhlbacher M, Nickel MK, Kettler C, et al. Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study. Clin J Pain. 2006;22(6):526-531.
141. Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Symptom Manage. 2003;25(5 Suppl):S31-35.
142. Jang Y, Kim ES, Park SS, Lee J, Moon DE. The suppressive effects of excarbazepine on mechanical and cold allodynia in a rat model of neuropathic pain. Anesth Analg. 2005;101(3):800-806.
143. Fox A, Gentry C, Patel S, Kesingland A, Bevan S. Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig. Pain. 2003;105(1-2):355-362.
144. Vuckovic SM, Tomic MA, Stepanovic-Petrovic RM, Ugresic N, Prostran MS, Boskovic B. The effects of alpha2-adrenoceptor agents on anti-hyperalgesic effects of carbamazepine and oxcarbazepine in a rat model of inflammatory pain. Pain. 2006;125(1-2):10-19.
145. Criscuolo S, Auletta C, Lippi S, Brogi F, Brogi A. Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. Acta Neurol Scand. 2005;111(4):229-232.
146. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain. 2005;9(5):543-554.
147. Laughlin TM, Tram KV, Wilcox GL, Birnbaum AK. Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J Pharmacol Exp Ther. 2002;302(3):1168-1175.
148. Novak V, Kanard R, Kissel JT, Mendell JR. Treatment of painful sensory neuropathy with tiagabine: a pilot study. Clin Auton Res. 2001;11(6):357-361.
149. Todorov AA, Kolchev CB, Todorov AB. Tiagabine and gabapentin for the management of chronic pain. Clin J Pain. 2005;21(4):358-361.
150. Ardid D, Lamberty Y, Alloui A, Coudore-Civiale MA, Klitgaard H, Eschalier A. Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats. Eur J Pharmacol. 2003;473(1):27-33.
151. Price MJ. Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain. 2004;20(1):33-36.
152. Biton V. Zonisamide: newer antiepileptic agent with multiple mechanisms of action. Expert Rev Neurother. 2004;4(6):935-943.
153. Atli A, Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med. 2005;6(3):225-234.
154. Solaro C, Messmer Uccelli M, Uccelli A, Leandri M, Mancardi GL. Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol. 2000;44(1):45-48.
155. Codd EE, Martinez RP, Molino L, Rogers KE, Stone DJ, Tallarida RJ. Tramadol and several anticonvulsants synergize in attenuating nerve injury-induced allodynia. Pain. In press.
156. Nishiyama T, Hanaoka K. The synergistic interaction between midazolam and clonidine in spinally-mediated analgesia in two different pain models in rats. Anesth Analg. 2001;93(4):1025-1031.
157. Talarek S, Fidecka S. Role of nitric oxide in benzodiazepines-induced antinociception in mice. Pol J Pharmacol. 2002;54(1):27-34.
158. Di Piero V, Ferracuti S, Sabatini U, et al. Diazepam effects on the cerebral responses to tonic pain: a SPET study. Psychopharmacology. 2001;158(3):252-258.
159. Szekely JI, Torok K, Mate G. The role of ionotropic glutamate receptors in nociception with special regard to the AMPA binding sites. Curr Pharm Des. 2002;8(10):887-912.
160. France RD, Kirshman KR. Psychotropic drugs in chronic pain. In: Chronic Pain. France RD, Kirshman KR, ed. Washington, DC: American Psychiatric Association; 1988.
161. Sawynok J. GABAergic mechanisms of analgesia: an update. Pharmacol Biochem Behav. 1987;26(2):463-474.
162. Rady JJ, Fujimoto JM. Confluence of antianalgesic action of diverse agents through brain interleukin (1beta) in mice. J Pharmacol Exp Ther. 2001;299(2):659-665.
163. Freye E, Latasch L. Development of opioid tolerance - molecular mechanisms and clinical consequences. Anasthesiol Intensivmed Notfallmed Schmerzther. 2003;38(1):14-26.
164. Hollister LE, Conley FK, Britt R, Shuer L. Long-term use of diazepam. JAMA. 1981;246(14):1568-1570.
165. King SA, Strain JJ. Benzodiazepine use by chronic pain patients. Clin J Pain. 1990;6(2):143-147.
166. Dellemijn PL, Fields HL. Do benzodiazepines have a role in chronic pain management? Pain. 1994;57(2):137-152.
167. Bartusch SL, Sanders BJ, D'Alessio JG, Jernigan JR. Clonazepam for the treatment of lancinating phantom limb pain. Clin J Pain. 1996;12(1):59-62.
168. McLean W, Boucher EA, Brennan M, Holbrook A, Orser R, Peachey J, Sellers E. Is there an indication for the use of barbiturate-containing analgesic agents in the treatment of pain? Guidelines for their safe use and withdrawal management. Canadian Pharmacists Association. Can J Clin Pharmacol. 2000;7(4):191-197.
169. Taricco M, Adone R, Pagliacci C, Telaro E. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev. 2000;(2):CD001131.
170. Sullivan M, Toshima M, Lynn P, Roy-Byrne P. Phenobarbital versus clonazepam for sedative-hypnotic taper in chronic paian patients. A pilot study. Ann Clin Psychiatry. 1993;5(2):123-128.
171. Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology. 1988;38(9):1427-1432.
172. Yosselson-Superstine S, Lipman AG, Sanders SH. Adjunctive antianxiety agents in the management of chronic pain. Isr J Med Sci. 1985;21(2):113-117.
173. Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des. 2002;8(1):45-58.
174. Hendler N, Cimini C, Ma T, Long D. A comparison of cognitive impairment due to benzodiazepines and to narcotics. Am J Psychiatry. 1980;137(7):828-830.
175. Cicccone DS, Just N, Bandilla EB, Reimer E, Ilbeigi MS, Wu W. Psychological correlates of opioid use in patients with chronic nonmalignant pain: a preliminary test of the downhill spiral hypothesis. J Pain Symptom Manage. 2000;20(3):180-192.
176. Caplehorn JR, Drummer OH. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health. 2002;26(4):358-362.
177. Ernst E, Bartu A, Popescu A, Ileutt KF, Hansson R, Plumley N. Methadone-related deaths in Western Australia 1993-99. Aust N Z J Public Health. 2002;26(4):364-370.
178. Merskey H. Pharmacological approaches other than opioid in chronic non-cancer pain management. Acta Anaesthesiol Scand. 1997;41(1 Pt 2):187-190.
179. Patt RB, Proper G, Reddy S. The neuroleptics as adjuvant analgesics. J Pain Symptom Manage. 1994;9(7):446-453.
180. Cendan CM, Pujalte JM, Portillo-Salido E, Baeyens JM. Antinociceptive effects of haloperidol and its metabolites in the formalin test in mice. Psychopharmacology. 2005;182(4):485-493.
181. Fishbain DA, Cutler RB, Lewis J, Cole B, Rosomoff RS, Rosomoff HL. Do the second-generation "atypical neuroleptics" have analgesic properties? A structured evidence-based review. Pain Med. 2004;5(4):359-365.
182. Pridmore S, Samilowitz H, Oberoi G. Will the atypical antipsychotics be analgesics? Australas Psychiatry. 2003;11:59-61.
183. Schreiber S, Backer MM, Weizman R, Pick CG. Augmentation of opioid induced antinociception by the atypical antipsychotic drug risperidone in mice. Neurosci Lett. 1997;228(1):25-28.
184. Schreiber S, Getslev V, Backer MM, Weizman R, Pick CG. The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharmacol Biochem Behav. 1999;64(1):75-80.
185. Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S. The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol. 2003;478(2-3):155-159.
186. Janicak P, Dowd S, Strong M, Minhas-Pannu S. The role of risperidone in the management of mood disorders. Psychiatr Ann. 2002;32:733-738.
187. Aigner M, Ossege M, Sycha T. Neuroleptics for acute and chronic pain (Protocol). Cochrane Database Syst Rev. 2004;(3):CD004844.
188. Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H. Altered dopaimine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord. 2003;75(1):77-82.
189. Hidalgo J, Rico-Villademoros F, Calandre EP. An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(1):71-77.
190. Rico-Villademoros F, Hidalgo J, Dominguez I, Garcia-Leiva JM, Calandre EP. Atypical antipsychotics in the treatment of fibromyalgia: a case series with
191. Calandre EP, Hidalgo J, Rico-Villademoros F. Use of ziprasidone in patients with fibromyalgia: a case series. Rheumatol Int. 2007;27:473-476.